病理生物学导向是抗血小板治疗的未来方向
颜红兵,霍勇
摘要(Abstract)：
<正>长期以来,在早期和强化期以阿司匹林为基础加用一种P2Y_(12)抑制剂(替格瑞洛、普拉格雷或氯吡格雷)的双联抗血小板治疗(dual antiplatelet therapy,DAPT),是急性冠状动脉综合征(acute coronary syndrome,ACS)患者的标准治疗~([1])。ACS的病理基础是由冠状动脉粥样硬化斑块破裂导致血栓形成所致,而炎症引起胶原结构减弱导致薄帽状纤维粥样瘤破裂是斑块不稳定的机制。与稳定性冠
关键词(KeyWords)： 抗血小板治疗;病理生物学导向
基金项目(Foundation):
作者(Author): 颜红兵,霍勇
参考文献(References)：
- [1]Valgimigli M,Bueno H,Byrne RA,et al.2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology(ESC)and of the European Association for Cardio-Thoracic Surgery(EACTS).Eur Heart J,2018,39(3):213-260.
- [2]Ibanez B,James S,Agewall S,et al.2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2018,39(2):119-177.
- [3]Crea F,Libby P.Acute coronary syndromes:the way forward from mechanisms to precision treatment.Circulation,2017,136(12):1155-1166.
- [4]Partida RA,Libby P,Crea F,et al.Plaque erosion:a new in vivo diagnosis and a potential ma jor shif t in the management of patients with acute coronary syndromes.Eur Heart J,2018,39(22):2070-2076.
- [5]颜红兵,霍勇.急性冠状动脉综合征:认清本质指导实践.中国介入心脏病学杂志,2014,22(1):1-3.
- [6]Libby P,Loscalzo L,Ridker PM,et al.Inflammation,immunity,and infection in atherothrombosis:JACC review topic of the week.JAm Coll Cardiol,2018,72(17):2071-2081.
- [7]Cuisset T,Deharo P,Quilici J,et al.Benefit of switching dual antiplatelet therapy after acute coronary syndrome:the TOPIC(timing of platelet inhibition after acute coronary syndrome)randomized study.Eur Heart J,2017,38(41):3070-3078.